The European Medicines Agency (Ema) recommended this Thursday (23) to grant the marketing authorization for the anti-Covid vaccine of the French pharmaceutical company Valneva.
The injection is intended for use as a primary immunization in people aged 18-50 and is composed of whole inactivated (dead) particles of the original virus strain that cannot cause disease but trigger an immune response.
According to the EMA, citing the main study conducted, the Valneva vaccine triggers the production of higher levels of antibodies against the Sars-CoV-2 strain than AstraZeneca’s Vaxzevria immunizer.
Furthermore, the percentage of people who produced a high level of antibodies was similar for both vaccines.
Based on the data provided, the European agency also noted that it is not possible to draw conclusions on the ability to trigger the production of antibodies in people over the age of 50. Therefore, the vaccine is currently recommended for use only in people between the ages of 18 and 50.
This is the sixth vaccine recommended in the EU to protect against Covid-19 and will strengthen vaccination campaigns against the disease in the block.